Over the past decade, much progress has been made in the field of induced pluripotent stem cells (iPSCs). Disease-specific iPSC lines can be easily generated from the patient’s somatic cells. With the recent advances in developmental biology, next-generation sequencing, single-cell analysis, three-dimensional (3D) culture, tissue engineering, large quantities of disease-relevant cell types that are otherwise inaccessible can be produced in a dish. These platforms provide a powerful model system for studying disease pathology and drug screening. Recently, the use of genome editing technology not only allows precise genetic correction of disease-causing mutations or transgene insertion to enhance therapeutic efficiencies but also helps introducing mutation to healthy iPSCs which can be used to model the rare disorders. These genome engineering approaches offer great promise toward next-generation stem cell-based therapy, which helps broaden the clinical applicability and can be potentially applied for creating universal, off-the-shelf cell products.
This research topic aims to highlight recent advances in iPSCs in disease modeling and regenerative medicine. We welcome original research articles, review articles, methods, resources, and perspectives. Potential areas include, but are not limited to:
- Disease modeling using patient-derived or gene-edited isogenic iPSCs;
- Advanced technologies such as single-cell analysis, high-content screening, CRISPR screening, microfluidic chips, multi-omics approaches for phenotypic and functional characterization of iPSC derivatives;
- Development of new therapeutic approaches using iPSC model platforms;
- Generation of universal or hypoimmunogenic stem cells for cell-based therapy;
- Optimized protocol for differentiation of iPSCs into specific lineages;
- Novel 3D or organoid culture systems for generation of functional cell types;
- Efficient strategies for genetic correction of disease-specific iPSCs;
- iPSC-derived organoids as models for studying host-pathogen interaction
Over the past decade, much progress has been made in the field of induced pluripotent stem cells (iPSCs). Disease-specific iPSC lines can be easily generated from the patient’s somatic cells. With the recent advances in developmental biology, next-generation sequencing, single-cell analysis, three-dimensional (3D) culture, tissue engineering, large quantities of disease-relevant cell types that are otherwise inaccessible can be produced in a dish. These platforms provide a powerful model system for studying disease pathology and drug screening. Recently, the use of genome editing technology not only allows precise genetic correction of disease-causing mutations or transgene insertion to enhance therapeutic efficiencies but also helps introducing mutation to healthy iPSCs which can be used to model the rare disorders. These genome engineering approaches offer great promise toward next-generation stem cell-based therapy, which helps broaden the clinical applicability and can be potentially applied for creating universal, off-the-shelf cell products.
This research topic aims to highlight recent advances in iPSCs in disease modeling and regenerative medicine. We welcome original research articles, review articles, methods, resources, and perspectives. Potential areas include, but are not limited to:
- Disease modeling using patient-derived or gene-edited isogenic iPSCs;
- Advanced technologies such as single-cell analysis, high-content screening, CRISPR screening, microfluidic chips, multi-omics approaches for phenotypic and functional characterization of iPSC derivatives;
- Development of new therapeutic approaches using iPSC model platforms;
- Generation of universal or hypoimmunogenic stem cells for cell-based therapy;
- Optimized protocol for differentiation of iPSCs into specific lineages;
- Novel 3D or organoid culture systems for generation of functional cell types;
- Efficient strategies for genetic correction of disease-specific iPSCs;
- iPSC-derived organoids as models for studying host-pathogen interaction
